New blood test aims to catch cancers early in veterans

NCT ID NCT06523868

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a blood test called Galleri that looks for signs of many different cancers early. It involves 1,500 veterans who served on active duty for at least four years and are 45 or older. Researchers want to see how well the test finds cancer compared to standard screening methods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

GRAIL Galleri multi-cancer early detection blood test

What this could lead to

If successful, this could show that a simple blood test helps catch multiple cancers earlier in veterans, potentially improving survival and treatment options.

What could go wrong

This is an early-stage study with no control group, so results may not prove the test saves lives. False positives could lead to unnecessary procedures and anxiety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER DIAGNOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact